A Phase 4 interventional study of Zoledronic acid and vitamin D in Osteoporotic Fractures and Osteoporosis, Postmenopausal, sponsored by Susan L. Greenspan. Completed at 1 site in United States. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-09-26.
Sponsored by Susan L. Greenspan · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Osteoporotic Fractures with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Osteoporotic Fractures · United States.
Among the 13 studies in Osteoporotic Fractures with a site in United States, this one is one of 2 that started in 2016, is one of 3 in phase 4, and was the 5th registered.
87 studies on the registry are indexed under Osteoporotic Fractures; 22 are open to participants now.
Browse Osteoporotic Fractures studies →2 of the 13 studies in Osteoporotic Fractures with a site in United States are open now. Recruiting first, the newest first:
AO Foundation, AO Spine · Sites in United States, Argentina, Brazil and 11 more countries
Ages 50+
University of Alabama at Birmingham · Sites in United States
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Osteoporotic Fractures studies recruiting now, 9 (64%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 65 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 310 is above the median of 120 across 49 interventional studies indexed under Osteoporotic Fractures.
Median enrollment 193 across the 8 interventional studies, 205 across the 4 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 10 most frequent:
Susan L. Greenspan is the lead sponsor of 5 studies on the registry; none are open to participants now.
Susan L. Greenspan has 3 studies filed under Osteoporotic Fractures — fewer than ten, so there is no comparison to draw.
1 of the studies in Osteoporotic Fractures with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Osteoporotic Fractures with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to perform the first fracture reduction clinical trial with a potent antiresorptive agent (intravenous zoledronic acid) in the most vulnerable long-term care population.
Although close to 85% of frail women in long-term care (LTC) facilities have osteoporosis and the risk of osteoporotic fractures is nearly 10 times that of community dwelling elderly, few are treated and studies are scarce. It is postulated that in frail, LTC women an annual infusion of zoledronic acid, an antiresorptive therapy for osteoporosis, will:
To address these hypotheses, up to 1000 female LTC residents age 65 and older will be screened in order to enroll 310 eligible for randomization in a 3 year, randomized, double-blind, calcium and vitamin D controlled trial with the antiresorptive agent zoledronic acid. Use of an intravenous, once yearly agent avoids concerns of oral bisphosphonate side effects, poor absorption and burden on staff. Participants will reside in the long-term care settings associated with the Division of Geriatric Medicine, University of Pittsburgh and will include women with multiple comorbid conditions, functional and cognitive impairment, and limited mobility.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
women age ≥65 years including those using assistive devices to maximize generalizability if they:
Have:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Annual dose: intravenous zoledronic acid (Reclast) 5.0 mg; vitamin D (800 IU/daily) and calcium (approximately 1200 mg/daily, dietary + supplements)
Drug: Zoledronic acid · Dietary Supplement: vitamin D · Dietary Supplement: calcium
Annual dose: intravenous saline; vitamin D (800 IU/daily and calcium (approximately 1200 mg/daily, dietary + supplements)
Dietary Supplement: vitamin D · Dietary Supplement: calcium · Other: Saline
Annual intravenous 5.0 mg
Also known as: Reclast
800 IU daily
approximately 1200 mg (dietary and supplement)
Annual intravenous saline placebo
Non-traumatic Incidental Fractures (Vertebral and Nonvertebral [Identified by X-ray, CT, MRI, VFA Imaging] Per Person-year)
Number of fractures divided by number of person-years. Effectiveness of fracture reduction will be demonstrated by total non-traumatic incidental fractures (vertebral and nonvertebral \[identified by x-ray, CT, MRI, VFA imaging) except those viewed as severe trauma (fall from a height higher than a stool or chair or severe trauma other than a fall), cancer-related or fractures of the toes, finger or facial bones.
Time frame: 3 years
Recruitment will occur during the first 2 years of the grant cycle and take place in the determined long term care facilities.
| Milestone | Active Medication Group | Placebo Group |
|---|---|---|
| Started | 154 | 156 |
| Completed | 101 | 102 |
| Not completed | 53 | 54 |
Number of fractures divided by number of person-years. Effectiveness of fracture reduction will be demonstrated by total non-traumatic incidental fractures (vertebral and nonvertebral \[identified by x-ray, CT, MRI, VFA imaging) except those viewed as severe trauma (fall from a height higher than a stool or chair or severe trauma other than a fall), cancer-related or fractures of the toes, finger or facial bones.
| Fractures per person-year | Active Medication Group | Placebo Group |
|---|---|---|
| Non-traumatic Incidental Fractures (Vertebral and Nonvertebral [Identified by X-ray, CT, MRI, VFA Imaging] Per Person-year) | 1.06093 | 1.01563 |
Collected over Up to three years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Medication Group | 13/154 (8.4%) | 73/154 (47.4%) | 131/154 (85.1%) |
| Placebo Group | 19/156 (12.2%) | 80/156 (51.3%) | 130/156 (83.3%) |
| Event | Active Medication Group | Placebo Group |
|---|---|---|
| DeathGeneral disorders | 13/154 | 19/156 |
| FallInjury, poisoning and procedural complications | 9/154 | 7/156 |
| Chest painCardiac disorders | 8/154 | 7/156 |
| Urinary tract infectionRenal and urinary disorders | 4/154 | 8/156 |
| Hip fractureMusculoskeletal and connective tissue disorders | 6/154 | 4/156 |
| SyncopeNervous system disorders | 6/154 | 2/156 |
| Gastrointestinal hemorrhageGastrointestinal disorders | 5/154 | 6/156 |
| Atrial fibrillationCardiac disorders | 5/154 | 5/156 |
| Cardiac failure congestiveCardiac disorders | 5/154 | 5/156 |
| WeaknessGeneral disorders | 5/154 | 0/156 |
| Event | Active Medication Group | Placebo Group |
|---|---|---|
| FallInjury, poisoning and procedural complications | 59/154 | 59/156 |
| MyalgiaMusculoskeletal and connective tissue disorders | 31/154 | 17/156 |
| HeadacheNervous system disorders | 30/154 | 18/156 |
| NauseaGastrointestinal disorders | 22/154 | 14/156 |
| Influenza like illnessGeneral disorders | 22/154 | 9/156 |
| DiarrheaGastrointestinal disorders | 15/154 | 18/156 |
| Urinary tract infectionRenal and urinary disorders | 16/154 | 17/156 |
| FatigueGeneral disorders | 15/154 | 10/156 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 14/154 | 14/156 |
| Back painMusculoskeletal and connective tissue disorders | 13/154 | 11/156 |
Same as participant flow
| Age, Categorical(Participants) | Active Medication Group | Placebo Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 154 | 156 | 310 |
| Age, Continuous(years) | Active Medication Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 81.3 ± 7.9 | 79.9 ± 7.7 | 80.6 ± 7.8 |
| Sex: Female, Male(Participants) | Active Medication Group | Placebo Group | Total |
|---|---|---|---|
| Female | 154 | 156 | 310 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Active Medication Group | Placebo Group | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 4 |
| Not Hispanic or Latino | 151 | 155 | 306 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Active Medication Group | Placebo Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 11 | 10 | 21 |
| White | 142 | 146 | 288 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | Active Medication Group | Placebo Group | Total |
|---|---|---|---|
| United States | 154 | 156 | 310 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2016 to primary completion in Jun 2022, 77 months.
Results were first posted in Aug 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zoledronic Acid
Susan L. Greenspan